The Fairlight Global Small and Mid Cap Fund has retained a "4 IP" rating by Research IP, with a score of 3.77/5.
The Barrow Hanley Global Share Fund has retained its “4 IP” rating from Research IP with a score of 3.80/5.
Research IP flags the significant changes to the QuayStreet New Zealand Equity Fund investment team and ownership.
The Harbour T. Rowe Price Global Equity Fund has retained its "4 IP" rating by Research IP, with a score of 4.18/5.
The Harbour Australasian Equity Focus Fund has retained its "5 IP" rating by Research IP, with a score of 4.27/5.
The Harbour Long Short Fund has retrained its "4 IP" rating by Research IP, with a score of 3.83/5.
Research IP brings you the RIPPL Roundup each month to provide an early market snapshot for New Zealand and Australian financial advisers.
Research IP brings you the RIPPL Roundup each month to provide an early market snapshot for New Zealand and Australian financial advisers.
Magellan has announced that Hamish Douglass will take a medical leave of absence. With the recent departure of the CEO, relative underperformance and losing their largest mandate, is this the beginning of the end?
The Magellan Global Fund has retained its "5 IP" rating from Research IP, with a score of 4.40/5.